Pathology: breast cancer - adjuvant; la/mBC - HR positive; la/mBC - HR-positive - 1st line (L1);
breast cancer - adjuvant | la/mBC - HR positive | la/mBC - HR-positive - 1st line (L1) | ||
PENELOPE-B, 2021 | KCSG-BR15-10, 2019 | PENELOPE-B, 2021 | ||
palbociclib plus endocrine therapy | 3 | T1 | T1 | T1 |
endocrine therapy | 0 | T0 | T0 | |
capecitabine | 0 | T0 |